BLAINJECTIONINJECTABLE
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Mechanism of Action
CD38-directed Antibody Interactions
Pharmacologic Class:
CD38-directed Cytolytic Antibody
Indications (15)
lenalidomidedexamethasone for inductionconsolidation in newly diagnosed patientsdexamethasone in newly diagnosed patientsmelphalanprednisone in newly diagnosed patientsrefractory multiple myelomathalidomidedexamethasone in patientsa proteasome inhibitor multiple myeloma in combination with carfilzomibdexamethasone in patients with relapsedan immunomodulatory agentan immunomodulatory agent high-risk smoldering multiple myelomacyclophosphamidemyeloma
Clinical Trials (4)
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Started Aug 2025
486 enrolled
Refractory or Relapsed Multiple Myeloma
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
Started Jan 2025
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Started Sep 2024
8 enrolled
Hematologic MalignancyBone Marrow Transplant RejectionAcute Myeloid Leukemia (AML)+9 more
A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
Started Apr 2024